PLS Group (PLS) Q3 2026 TU earnings summary

Executive summary

• Achieved record quarterly production of 232,000–232.4kt of spodumene concentrate, up 12% sequentially, with strong operational performance and improved pricing driving significant financial gains.

• Revenue rose 52% quarter-on-quarter to AUD 567 million, driven by a 61% increase in realized prices for spodumene concentrate.

• Cash margin from operations increased 178% to AUD 461 million, with cash balance up 52% to AUD 1,455 million, supported by a US$100–141 million Canmax prepayment.

• Disciplined capital allocation and staged growth strategy maintained, with Ngungaju Plant restart approved and on track for July 2026; P2000 and Colina project studies progressing.

• FY26 guidance reaffirmed for all operational and financial metrics.

Financial highlights

• Realized price for spodumene concentrate surged 61% quarter-on-quarter to US$1,867/t (CIF China, SC5.2 basis).

• Unit FOB operating costs decreased 11% to AUD 520/t (US$362/t), while CIF unit costs rose 2% to AUD 733/t (US$510/t) due to higher royalties.

• Sales volumes were 195,000–195.7kt, with inventory build due to cyclone-related port congestion, expected to clear next quarter.

• Cash flow from operations and Canmax prepayment drove a cash increase of approximately AUD 500 million, closing with AUD 1,455 million.

• QP adjustments contributed around AUD 70 million to revenue.

Outlook and guidance

• FY26 guidance for production, unit costs, and capital expenditure reaffirmed; unit costs expected to rise in June quarter with Ngungaju restart.

• No material supply chain disruptions expected for FY26 despite geopolitical tensions.

• FY2027 capital allocation details to be provided with the June quarter update.

• Dividend distributions under consideration, targeting 20%-30% of free cash flow, subject to market conditions.

• Market tightness expected to persist, with strong lithium demand and potential supply gap through 2040.